AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases
The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept…
News
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Company also announces that Julia Haller, MD, is stepping down from its Board of Directors…
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
Company to Announce Lead Program During Podium Presentation CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE)…
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in…
Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
Conference Call to be Held on December 14th at 11:00 a.m. Eastern Time HOUSTON, Dec….
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi…
Canary Medical Announces Introduction of Groundbreaking Orthopedic Analytic Platform
Canary Quantiles™ Recovery Curves Compare Observed Gait Performance versus Population Gait Performance During a Patient’s Recovery…
Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022
LAS VEGAS, NV, Dec. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Digipath, Inc. (OTCQB:…
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic…
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO – IO) Annual Congress
– INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single…
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44%…
Sensei Biotherapeutics Provides Update on Strategic Priorities
– Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses…
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American…
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg…
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney Expansion CALGARY, Alberta, Dec. 08,…
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for…
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss…